Oncotarget Research Pioneers Therapeutic Options for Breast and Thyroid Cancers

link to article recap: https://www.researchgate.net/publication/322216785_The_effects_of_naloxone_on_human_breast_cancer_progression_in_vitro_and_in_vivo_studies_on_MDAMB231_cells

The enigma of human cell carcinoma and potential cures are tirelessly researched. Since 2010, peer-reviewed bio-medical journal, Oncotarget covers such ongoing oncology analysis and diligently publishes categories on a multitude of topics, including breast and thyroid cancers. Since human tumors respond to targeted cancer therapies different than say, rodent models, successful treatment remains elusive, time-consuming and exponentially expensive resulting in continued disease mortality. Watch this video on Youtube.

One example of inadequate pharmaceutical results in human breast cell line MDAMB231. While carcinoma research for this area of cells identified opioid receptor antagonist-drug naloxone as successful at inhibiting estrogen positive cells, it was only those specific cells that responded. Since cancer is more than just one disease, and every human patient has a unique combination of malignant cell function, finding a drug combination to inhibit each specific tumor cell growth continues to be inadequately researched for human cancer cell combinations. Rather, we spend resources to advance traditional chemo and radio-therapies.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

While time is so often the enemy, one neoteric strategy is offering hope for drug-resistant cancers. On the cusp of a cure for both breast and more recently, recurrent thyroid cancer patients, the already FDA approved treatment for metastatic breast cancer palbociclib has Oncotarget’s full attention. Recurrent carcinoma frustrates both patient and oncologists because the original treatment stops responding effectively, allowing cancer to return. Excitement over palbociclib is to the extent that it works as a stronger “combination” with the original drug therapy vemurafenib, to induce ultimate cancerous cell death versus single drug treatment.

Protein complex cancers, especially common in thyroid cases, are more aggressive. Highly aggressive types of thyroid and breast cancer require ultimate vigilance and ongoing surveillance throughout the stages of treatment. Despite cancers that progress to an incurable state, there are still combinations yet to be found that will ultimately prolong life and enhance the quality of life for those being treated with poor prognosis. Learn more about Oncotarget at Eurekalert.org.

Leave a Reply

Your email address will not be published. Required fields are marked *